Phase III studies in Japan on the anti-IGF-1 receptor antibody, AMG479, in-licensed from Amgen, were decided to be stopped, following Amgen’s move to terminate global trials in view of statistically insignificant improvements in the primary endpoint of overall survival

Takeda press release, August 9, 2012